146 related articles for article (PubMed ID: 16755917)
1. [The effect of oncolytic adenovirus on human umbilical vein endothelial cell].
Ye ZM; Wang XH; Zhong J; Miao JC; Sheng WH; Xie YF; Wang JZ; Yang JC
Sheng Wu Gong Cheng Xue Bao; 2006 May; 22(3):397-402. PubMed ID: 16755917
[TBL] [Abstract][Full Text] [Related]
2. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
3. [Construction of adenovirus vector expressing IL-24 and E1A and its inhibition of SMMC-7721].
Wang X; Miao J; Xie Y; Sheng W; Shan Y; Yang J
Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):1035-41. PubMed ID: 19835145
[TBL] [Abstract][Full Text] [Related]
4. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
5. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.
Fechner H; Wang X; Picó AH; Wildner J; Suckau L; Pinkert S; Sipo I; Weger S; Poller W
J Biotechnol; 2007 Jan; 127(4):560-74. PubMed ID: 17083991
[TBL] [Abstract][Full Text] [Related]
6. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
Bilsland AE; Merron A; Vassaux G; Keith WN
Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167
[TBL] [Abstract][Full Text] [Related]
7. [Construction of recombinant adenovirus vector of hNRAGE gene and its effect on cell cycle of 293 cells].
Zhou LH; Xue B; Guo SY; Shi YH; Wen CJ; Li CJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jan; 22(1):18-21. PubMed ID: 16388736
[TBL] [Abstract][Full Text] [Related]
8. [Construction of recombinant adenoviruses encoding TK suicide gene driven by VEGF promoter using efficient AdEasier-1 system].
Chen JF; Huang ZH; Huang YY; Song HJ; Che XY
Ai Zheng; 2004 Sep; 23(9):1093-7. PubMed ID: 15363210
[TBL] [Abstract][Full Text] [Related]
9. [Ad-ING4 inhibits K562 cell growth].
Yu X; Zhang HF; Wang JZ; Xie YF; Yang JC; Miao JC
Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):396-400. PubMed ID: 17939406
[TBL] [Abstract][Full Text] [Related]
10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
11. A three-plasmid system for construction of armed oncolytic adenovirus.
Liu HY; Han BJ; Zhong YX; Lu ZZ
J Virol Methods; 2009 Dec; 162(1-2):8-13. PubMed ID: 19646479
[TBL] [Abstract][Full Text] [Related]
12. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
13. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
15. Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells.
Hibma MH; Real NC; Wiles A; Dobson-Le D; Dix BR; Wynford-Thomas D; Braithwaite AW; Royds JA
Virus Res; 2009 Oct; 145(1):112-20. PubMed ID: 19576936
[TBL] [Abstract][Full Text] [Related]
16. [Preparation and functional study of an adenovirus vector expressing human plasminogen kringle 5 gene].
Yang J; Wang YX; Guan XQ; Ma CG; Wang LS; Song HY
Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):217-22. PubMed ID: 15966325
[TBL] [Abstract][Full Text] [Related]
17. Optimization of an E1A Gene Expression Cassette in an Oncolytic Adenovirus for Efficient Tumor Cell Killing Activity.
Sakurai F; Nishimae F; Takayama K; Mizuguchi H
Anticancer Res; 2021 Feb; 41(2):773-782. PubMed ID: 33517282
[TBL] [Abstract][Full Text] [Related]
18. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
19. A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy.
Wei N; Fan JK; Gu JF; He LF; Tang WH; Cao X; Liu XY
Biochem Biophys Res Commun; 2009 Oct; 388(2):234-9. PubMed ID: 19653996
[TBL] [Abstract][Full Text] [Related]
20. Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.
Farson D; Tao L; Ko D; Li Q; Brignetti D; Segawa K; Mittelstaedt D; Harding T; Yu DC; Li Y
Mol Ther; 2006 Aug; 14(2):305-11. PubMed ID: 16697707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
